Therapeutic potential of a novel multifunctional iron chelator on cognitive decicits and insulin degrading enzyme expression in a rat model of sporadic Alzheimer's disease
© Knezović et al; licensee BioMed Central Ltd. 2012
Published: 17 September 2012
There is a need in modern pharmacology for a representative animal model which should accurately mimic sporadic Alzheimer’s disease (sAD), the prevailing type of dementia in humans, and thus could be suitable for novel drug testing. Rats treated intracerebroventricularly with the betacytotoxic agent streptozotocin (STZ-icv), have been proposed recently as a non-transgenic sAD model which demonstrates AD-like pathology features at cognitive, neurochemical and structural level. In addition to the cognitive deficits, pathological accumulation of amyloid β (Aβ) peptide is one of the neuropathological hallmarks of sAD, and a growing body of evidence suggests the involvement of insulin degrading enzyme (IDE), responsible for Aβ degradation, in sAD pathophysiology. We have explored the time course of cognitive deficits and hippocampal (HPC) IDE expression in the STZ-icv rat model of sAD, and the therapeutic potential of the novel multifunctional iron-chelating drug M30 to improve these deficits.
Adult Male Wistar rats were injected bilaterally icv with STZ (0.3, 1 and 3 mg/kg) or vehicle and sacrificed one week, or one, three, six and nine months after the treatment. Two groups of STZ-icv (3 mg/kg)-injected rats were additionally subjected to an 11-week oral M30 treatment (2 and 10 mg/kg, 3x per week) beginning 10 days after the STZ-icv treatment. Cognitive deficits were measured by the Morris water maze swimming test (MWM) and the passive avoidance test (PA). IDE protein expression in HPC was measured by SDS-PAGE electrophoresis/immunoblotting. Data were analysed by the Kruskal-Wallis and the Mann-Whitney U test (p < 0.05).
STZ-icv rats exhibited significant dose- and time-dependent cognitive deficits in the PA test (40–90%), while IDE protein expression was found to be decreased not earlier than one month after the STZ-icv administration (−56%), persisting decreased untill six months (−26%). Treatment with the high M30 dose improved STZ-icv-induced cognitive deficits, observed as a decreased number of mistakes in the MWM test (−60%) and increased latency time in the PA test (+300%). Treatment with both M30 doses significantly increased IDE protein expression in comparison with the STZ-icv treatment alone (low dose +19%, high dose +37%).
The STZ-icv rat model demonstrates long-term cognitive deficits and decreased hippocampal IDE protein expression which tend to correlate mutually. Chronic M30 treatment, initiated after the development of cognitive deficits, significantly improves the cognitive deficits as well as decreases IDE protein expression in the STZ-icv rat model of sAD, suggesting that multifunctional iron-chelating drugs might have a therapeutic potential in sAD treatment.
Supported by UKF, MZOS and DAAD.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.